Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): P014
Therapeutic Area: Immunology Product Name: P014
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Quan Capital
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 12, 2020
Details:
Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IgG-like bispecific antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 20, 2020
Details:
Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antisense oligonucleotide therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 05, 2020
Details:
Partnership creates an opportunity for biotech and pharmaceutical companies to enter the growing field of antisense therapeutics by partnering with Evotec and Secarna and to gain access to the companies' co-owned pipeline through a variety of individual deal structures.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Engineered Regulatory T cell therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gentbio
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 05, 2020
Details:
Under the terms of the licensing agreements, Seattle Children’s, BRI and MIGAL will exclusively licenseunique technologies to GentiBio that overcome many of the current limitations of Tregs therapeutics,including rarity and plasticity of endogenous Tregs populations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hypoimmunogenic cells
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 29, 2020
Details:
First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
